尽管隆培生长激素的官方定价尚未公布，但市场对其讨论热度居高不下。参考全球定价，该产品在美国 的年治疗成本高达50万至60万元，而国内市场普遍预判，其本土年治疗费用将大幅低于这一水平。这种 兼顾品质与性价比的潜在优势，进一步放大了市场期待。 一旦这条路径走通，不仅能帮助维昇药业抢占高端市场先机，更有望推动整个生长激素赛道的发展逻辑 重构，这将是一个不同于以往的里程碑式转折。 近日，维昇药业核心产品隆培生长激素注射液（维臻高，Skytrofa）获批上市，用于治疗儿童生长激素 缺乏症（PGHD），是全球唯一优效于日制剂的长效生长激素。 自此，国内长效生长激素阵营已扩容至4款产品，呈现出鲜明的分化特征。其中，唯有隆培生长激素采 用天然分子结构，与人体自身分泌的生长激素氨基酸序列完全一致，而其余产品均为重组分子结构。 可以说，隆培生长激素的登场，既是维昇药业瞄准市场痛点的一次差异化布局，更是长效生长激素赛道 的一次突破性"社会实验"。 2月2日，维昇药业召开投资人交流会，与投资者展开深度交流，围绕这款产品的临床价值与未来商业化 路径，主动、清晰且坦诚地向市场传递公司的判断与战略思考。 唯一实现迭代性突破的产品，拥有独特 ...

全球医药圈突发巨震。 这次减肥药双雄比拼的主角是：诺和诺德的CagriSema，和礼来的Zepbound。 不过，此次对决以诺和诺德惨败结束。 据诺和诺德发布声明称，接受标准剂量实验药物CagriSema治疗的受试者在84周后体重减轻了20.2%。 相比之下，礼来的替尔泊肽（Tirzepatide）减重效果为23.6%。 CagriSema为诺和诺德开发的一款复方药物，包含长效胰淀素（amylin）类似物Cagrilintide与GLP-1受体 激动剂司美格鲁肽。 全球减肥药"霸主"诺和诺德因新药不及竞争对手礼来，迎来史诗级暴跌。 周一美股收盘，诺和诺德股价大跌超16%，股价跌至2021年6月以来的最低点，市值大幅缩水至1769.48 亿美元。 相反，礼来因减肥药的升级，股价向上收涨4.8%，现总市值9986亿美元。 诺和诺德惨败 减肥药格局生变？ 对比来看，对手礼来则在突飞猛进。 去年12月，诺和诺德向 FDA 提交了 CagriSema 的审批申请，该制药商表示预计将在 2026 年底做出决 定。 诺和诺德原本寄希望于CagriSema能成为其现有药物Wegovy(将于2030年后专利到期)的强力继任者， ...

消息面上，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济 药业-B(02659)获纳入恒生综合指数。此次变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日 (星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据LiveReport大数据预测，宝济 药业有望借此机会纳入港股通，迎来发展新契机。 据悉，宝济药业拥有中国首款报产的重组人透明质酸酶的KJ017，用于大容量皮下给药;全球首款在低预 存抗体和给药次数方面具备"同类最佳"潜力的IgG降解酶KJ103，用于抗体介导的自身免疫性疾病; 以及 一款已获得合作验证的长效促卵泡激素药物SJ02，用于辅助生殖。西牛证券指出，就即将及正在商业化 的产品而言，宝济药业己经订下明确的商业化模式及时间表。其中，目前重组人透明质酸酶并无作为单 药疗法在中国市场销售，KJ017预计于2026年首季获得NDA批准。 智通财经APP获悉，宝济药业-B(02659)逆市涨超6%，盘中高见190港元创新高，截至发稿，涨6.09%， 报190港元，成交额2805.61万港元。 ...

Core Viewpoint - AbbVie plans to invest $380 million to build two new active pharmaceutical ingredient production facilities in Illinois, USA, to expand its domestic production capacity for neuroscience and weight loss drugs [1] Group 1: Investment Details - The investment of $380 million will be directed towards the construction of new production facilities [1] - AbbVie already operates 11 production sites in the United States [1] - The company is in discussions with multiple states regarding potential projects and expects to announce further investments this year [1]

【财华社讯】长风药业(02652.HK)公布，公司自主研发的吸入粉雾剂候选药物ICF004新药临床试验 ("IND")申请已获中国国家药品监督管理局("NMPA")受理。ICF004拟用于治疗进行性纤维化间质性肺 病，该疾病领域包括特发性肺纤维化及进行性肺纤维化等危及生命的适应症。ICF004采用吸入乾粉给 药途径，旨在将药物直接递送至肺部病变区域，从而增加肺部局部暴露量，同时尽可能降低全身暴露 量，以期实现疗效与安全性之间更为有利的平衡。 本文源自：财华网 ...

Market Overview - On February 23, US stock indices faced pressure due to uncertainty surrounding tariff rulings and concerns over AI development, resulting in a collective decline. The Dow Jones fell by 1.66% to 48,804.06 points, the S&P 500 dropped by 1.04% to 6,837.75 points, and the Nasdaq decreased by 1.13% to 22,627.27 points [1] Company-Specific Developments - IBM's stock plummeted over 13%, marking its largest single-day drop since October 2000. This decline is attributed to competitive pressures from Anthropic's Claude Code, which targets IBM's reliance on legacy COBOL systems [3][7] - Other notable stock movements included Novo Nordisk, which fell over 16%, and a 32.75% drop in the 2x Long Novo Nordisk ETF, following disappointing clinical trial results for its product CagriSema compared to Eli Lilly's Zepbound. Conversely, Arcellx's stock surged over 77% due to a reported acquisition by Gilead Sciences at $115 per share [8] Tariff and Economic Policy - The US Customs and Border Protection (CBP) announced the cessation of tariffs imposed under the International Emergency Economic Powers Act (IEEPA) following a Supreme Court ruling deeming them illegal. This change is expected to influence market dynamics throughout the year [4][5] - Market analysts have differing views on the impact of tariffs. Michael Landsberg from Landsberg Bennett Private Wealth Management suggests that ongoing tariff negotiations may continue to disrupt the market, while Edward Jones' Angelo Kourkafas downplays the potential economic impact of increasing tariffs to 15% [5] Commodity Market Reaction - In response to the tariff situation, precious metals experienced gains, with COMEX gold futures rising by 0.7% to $5,262.3 and COMEX silver futures increasing by 2.18% to $88.46 [9]

经济观察网 金陵药业子公司补缴税款841.15万元，核心募投项目延期两年，同时公司利用闲置募资进行 理财管理。 近期事件 子公司宿迁医院需补缴2022年至2024年期间税款及滞纳金841.15万元，目前已全部缴纳完毕。该事项可 能对财务表现产生短期影响。 子公司赎回两笔募资理财获利270.97万元，并新购总额15,600万元结构性存款，期限360天。截至公告 日，未到期募资理财余额为68,000万元。 股票近期走势 股价报7.99元/股，当日上涨2.04%，主力资金净流入94.94万元；2025年1-9月营收23.80亿元，归母净利 润6,845.83万元。股东户数截至1月30日为3.35万户，较上期减少1.98%。 行业政策与环境 医药行业在2026年面临集中度提升、创新药支持政策深化等趋势，可能对公司转型形成外部驱动。 以上内容基于公开资料整理，不构成投资建议。 公司项目推进 公司宣布将"核心原料药及高端医药中间体共性生产平台建设项目"达产日期从原定2026年3月延期至 2028年3月，截至2025年9月底投资进度仅2.57%。项目延期可能影响长期产能布局。 资金动向 ...

Core Viewpoint - The publication of the Phase 1b clinical study results for the AKT inhibitor Afuresertib (LAE002) in combination with Fulvestrant for HR+/HER2- advanced breast cancer demonstrates promising efficacy and safety, highlighting the potential for significant market opportunities in the treatment of this prevalent cancer subtype [1][3][18] Group 1: Clinical Study Insights - The Phase 1b study led by Academician Xu Binghe shows that Afuresertib combined with Fulvestrant exhibits potential efficacy and safety in patients with PIK3CA/AKT1/PTEN pathway alterations [1][5] - The ongoing Phase III study (AFFIRM-205) is expected to report data in the first half of 2026, with the Phase 1b results providing increased confidence for positive outcomes in the upcoming trial [1][15] - The Phase 1b study included a significant proportion of patients who had previously failed CDK4/6 inhibitor treatment, showcasing the potential of Afuresertib in this challenging patient population [7][8] Group 2: Market Potential - The global breast cancer drug market is projected to grow from approximately $38.2 billion in 2023 to $71.2 billion by 2032, with the HR+/HER2- subtype representing 60%-75% of breast cancer cases [3][16] - The market for second-line treatments for HR+/HER2- breast cancer, particularly those with PIK3CA/AKT1/PTEN alterations, is expected to be substantial, with estimates suggesting a market size of around 5 billion RMB [16] - Afuresertib's potential market share is estimated at 25%-30%, which could translate to sales peaks of approximately 1.5 billion RMB [16] Group 3: Competitive Landscape - Afuresertib's safety profile is highlighted as a competitive advantage over other AKT inhibitors like Capivasertib and Alpelisib, which have shown higher rates of adverse effects [11][12] - The Phase 1b study reported a 0% incidence of grade 3 hyperglycemia and a low rate of other adverse events, indicating a favorable safety profile that may enhance patient compliance [12][14] - The commercial success of Afuresertib is anticipated to be bolstered by its safety and efficacy, positioning it as a leading option in the AKT inhibitor market [11][14]

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 FDA 创新药审评政策再松绑，利好创新药板 块 增持（维持） [Table_Tag] [Table_Summary] 投资要点 《降息等多因素支持科研上游持续复 苏，重点推荐皓元医药、奥浦迈等》 2026-02-01 东吴证券研究所 1 / 24 请务必阅读正文之后的免责声明部分 2026 年 02 月 23 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 20% 23% 2025/2/24 2025/6/22 2025/10/18 2026/2/13 医药生物 沪深300 相关研究 《分子胶海外风起，国内管线蓄势破 局》 2026-02-09 ◼ 本周（2.9-2.13 号，下同）、年初至今 A 股医药指数涨幅分别为-0.8%、 2.4%，相对沪深 300 的超额收益分别为-1.2%、1.8%；本周、年初至今 恒生生物科技指数涨跌幅分别为 4.8%、12.5%，相对于恒生科技指数跑 赢 7.3%、18.0%；本周 ...

Important Events - BGI Genomics plans to sell 100% equity of Complete Genomics for $50 million and adjust the licensing of CoolMPS sequencing technology [1] - Base Pharmaceuticals received approval from the UK MHRA for Sugli monoclonal antibody's new indication in non-small cell lung cancer [1] - Frontline Bio signed a licensing agreement with GlaxoSmithKline, receiving an upfront payment of $40 million and potential milestone payments totaling up to $950 million (approximately 6.56 billion RMB) [1] - Bai Li Tian Heng's clinical trial for iza-bren (EGFR×HER3 dual antibody ADC) in locally advanced or metastatic triple-negative breast cancer reached its primary endpoint in interim analysis [1] - Huagong Technology's AI high-speed optical module orders are scheduled to run through the fourth quarter, with production bases in Wuhan and Thailand fully operational [1] - Wuliangye has distributed over 76.8 billion RMB in dividends over the past five years [1] - Tongfu Microelectronics' application for a specific stock issuance has been accepted by the Shenzhen Stock Exchange [1] Bids - Donghong Co., Ltd. won a procurement project for pressure steel pipes and accessories worth 353 million RMB [1] - Jintanglan's subsidiary won a project for the Sabah Intercontinental Resort Hotel in Malaysia, amounting to approximately 281 million RMB [1] - Shuangliang Energy's wholly-owned subsidiary won a bid for the cooling island system of an H-class combined cycle power plant project in the Middle East, with a bid amount of 100.26 million RMB [1] Performance - Jiantao Group expects a more than 165% increase in net profit for 2025 compared to the same period in 2024 [1] Buybacks & Increases - Luxshare Precision conducted its first share buyback, repurchasing 9.9 million shares for nearly 500 million RMB [2] - Tongce Medical's chairman and others plan to increase their holdings in the company by 6 to 12 million RMB [2]